Drugs / STW5
STW5
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04059900 | Jun 2009 → May 2013 | — | Bayer | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01940848 | Oct 2013 → Oct 2017 | irritable bowel syndrome | Bayer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04656730 | Sep 2020 → Jan 2023 | dyspepsia, irritable bowel syndrome | Hospital Vall d'Hebron | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STW 5 | “Iberogast® (STW 5) in Patients With Functional Dyspepsia and Concomitant Reflux Symptoms” NCT04059900 ↗4“STW5 (Iberogast®) is a medicinal product composed by 9 herbal preparations” NCT04656730 ↗ “Applied orally over 28 days, 20 drops STW 5 three times daily” NCT01940848 ↗ |
| Known as | BAY98-7411 | “STW5 (Iberogast®, BAY98-7411)” NCT04059900 ↗1“STW5 (Iberogast, BAY98-7411)” NCT01940848 ↗ |
| Known as | Iberogast | “STW5 (Iberogast®) is a medicinal product composed by 9 herbal preparations” NCT04656730 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “STW5 (Iberogast®) is a medicinal product composed by 9 herbal preparations” NCT04656730 ↗ |
| Route | Oral | “Applied orally over 28 days, 20 drops STW 5 three times daily” NCT01940848 ↗ |